Get the Stockscreener App
76.13
1.60%
1.20
After Hours:
76.13
Nuvalent Inc stock is traded at $76.13, with a volume of 220.18K.
It is up +1.60% in the last 24 hours and down -6.49% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$74.93
Open:
$74.6
24h Volume:
220.18K
Relative Volume:
0.45
Market Cap:
$5.08B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-19.52
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+3.95%
1M Performance:
-6.49%
6M Performance:
+1.63%
1Y Performance:
-9.67%
1-Day Range:
$74.57
$76.34
1-Week Range:
$71.68
$76.44
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
76.13 | 5.40B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Long term hold vs stop loss in Nuvalent Inc.Weekly Market Report & Risk Controlled Swing Alerts - Newser
Evaluating Nuvalent Inc. with trendline analysisJuly 2025 Intraday Action & Community Consensus Trade Alerts - Newser
Is Nuvalent Inc. stock entering bullish territoryIPO Watch & Free Technical Pattern Based Buy Signals - Newser
Nuvalent Inc. Approaches Psychological Resistance Level getLinesFromResByArray error: size == 0 - 더경남뉴스
Using Bollinger Bands to evaluate Nuvalent Inc.Portfolio Return Summary & Weekly Stock Breakout Alerts - Newser
Can Nuvalent Inc. recover in the next quarter2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - Newser
Detecting price anomalies in Nuvalent Inc. with AIEntry Point & Verified Momentum Watchlists - Newser
Can technical indicators confirm Nuvalent Inc.’s reversalPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
How to integrate Nuvalent Inc. into portfolio analysis tools2025 Dividend Review & Real-Time Market Trend Scan - Newser
Published on: 2025-08-26 14:16:31 - Newser
How moving averages guide Nuvalent Inc. tradingSell Signal & Verified Short-Term Trading Plans - Newser
Nuvalent Inc. stock outlook for YEARJuly 2025 Chart Watch & Precise Entry and Exit Recommendations - Newser
Why Nuvalent Inc. stock attracts strong analyst attentionWeekly Gains Report & Risk Controlled Swing Trade Alerts - 더경남뉴스
Will Nuvalent Inc. Stock Benefit from AI and Green Energy TrendsPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
Pattern recognition hints at Nuvalent Inc. upsideJuly 2025 Snapshot & Risk Controlled Daily Trade Plans - Newser
Is Nuvalent Inc.’s ROIC above industry averageWeekly Trend Report & Daily Risk Controlled Trade Plans - theviewers.co.kr
Is Nuvalent Inc. stock overvalued or fairly pricedDay Trade & High Accuracy Trade Alerts - theviewers.co.kr
Will breakout in Nuvalent Inc. lead to full recovery2025 Technical Overview & Low Drawdown Trading Strategies - Newser
Key metrics from Nuvalent Inc.’s quarterly dataTrade Entry Summary & Precise Buy Zone Identification - Newser
Developing predictive dashboards with Nuvalent Inc. dataTrade Entry Report & High Accuracy Trade Alerts - Newser
Will Nuvalent Inc. stock recover after recent dropJuly 2025 Review & Technical Pattern Recognition Alerts - Newser
Regression Model Predicts Rangebound Movement in Nuvalent Inc.2025 Pullback Review & Momentum Based Trading Signals - 클래시안
Leading vs lagging indicators on Nuvalent Inc. performanceEarnings Recap Summary & Growth Focused Investment Plans - Newser
What machine learning models say about Nuvalent Inc.2025 Market Sentiment & Stepwise Entry/Exit Trade Alerts - Newser
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
Piper Sandler initiates Nuvalent stock coverage with Overweight rating - Investing.com
Piper Sandler initiates Nuvalent stock coverage with Overweight rating By Investing.com - Investing.com UK
Is Nuvalent Inc. showing insider buying2025 EndofYear Setup & Stepwise Entry and Exit Trade Signals - newsimpact.co.kr
What makes Nuvalent Inc. stock price move sharplyIPO Watch & Community Verified Trade Signals - Newser
Will a bounce in Nuvalent Inc. offer an exitMarket Movers & Weekly Consistent Profit Watchlists - Newser
Sentiment analysis tools applied to Nuvalent Inc.Weekly Earnings Recap & AI Powered Buy/Sell Recommendations - Newser
Backtesting results for Nuvalent Inc. trading strategiesWeekly Trend Summary & Entry Point Confirmation Signals - Newser
Nuvalent Inc. Hits Oversold Level on RSI Indicator2025 Key Highlights & Real-Time Sentiment Analysis - metal.it
Is Nuvalent Inc. stock a buy or sellJuly 2025 Weekly Recap & Community Driven Trade Alerts - mustnews.co.kr
What’s the recovery path for long term holders of Nuvalent Inc.2025 Major Catalysts & Real-Time Volume Spike Alerts - Newser
Is Nuvalent Inc. in a bullish channel2025 Bull vs Bear & Stepwise Entry/Exit Trade Alerts - thegnnews.com
Heatmap Data Shows High Activity in Nuvalent Inc. Sector2025 Price Action Summary & Daily Stock Trend Reports - 선데이타임즈
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year - Investing.com
Inhibrx Awaits Ozekibart Clinical Data in October - AInvest
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - The Malaysian Reserve
Nuvalent to present pivotal lung cancer drug data at WCLC 2025 - Investing.com Nigeria
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):